Lymphoma research includes advances in immunotherapy, targeted agents, and personalized treatment based on molecular subtypes.
A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.
Single-center, nonrandomized Phase 1 dose-exploration trial of META 10-19 — a CD19 CAR T-cell product engineered to also express interleukin-10 — delivered at ultralow cell doses to 13 heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).